文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

Pexidartinib联合放疗与雄激素剥夺治疗中高危前列腺癌的1期研究

A Phase 1 study Combining Pexidartinib, Radiation Therapy, and Androgen Deprivation Therapy in Men With Intermediate- and High-Risk Prostate Cancer.
PubMed 文献 · Adv Radiat Oncol · 2021-03-03

这项1期研究评估了放疗、雄激素剥夺治疗(ADT)与CSF1R抑制剂pexidartinib联合用于中危和高危前列腺癌患者。4例可评估患者中,3例出现6起不良事件,其中5起为3级毒性且归因于pexidartinib,符合剂量限制性毒性标准,最终导致研究关闭。结论为联合方案耐受性不佳,不值得进一步研究。

要点

  • 4例患者中3例出现6起不良事件,5起为归因于pexidartinib的3级毒性。
  • 5起3级毒性符合剂量限制性毒性标准,最终导致研究关闭。
  • 联合方案耐受性不佳,不推荐在中高危前列腺癌中进一步研究。

核心结论

  • 放疗、ADT与pexidartinib联合方案耐受性不佳,不值得在中危和高危前列腺癌男性中进一步研究。

研究设计与样本

  • 1期研究,入组4例可接受放疗的T1期前列腺癌患者,其中2例中危、2例高危。
  • 治疗方案为pexidartinib 800 mg分两次每日给药联合ADT共6个月,放疗于第3个月初开始。
  • 放疗靶区包括前列腺和近端精囊,处方剂量7920 cGy(180 cGy/次),采用调强放疗每日图像引导定位。
  • 主要目标为基于剂量限制性毒性确定最大耐受剂量。

主要发现

  • 4例患者中位年龄62.5岁,前列腺特异性抗原范围6.4至10.7 ng/mL,Gleason评分分别为3+3、4+3、4+4和4+5。
  • 所有4例患者在放疗前均报告至少1起不良事件。
  • 1例出现1级色素减退,另1例出现3级肺栓塞。
  • 1例出现疲劳和关节痛,另1例出现淀粉酶升高和瘙痒,均为3级毒性。
  • 3例患者共报告6起不良事件,其中5起为归因于pexidartinib的3级毒性,符合剂量限制性毒性标准并最终导致研究关闭。

关键数值与推荐

  • pexidartinib剂量为800 mg,分两次每日给药,与ADT共同持续6个月。
  • 放疗剂量为7920 cGy,每次180 cGy,采用调强放疗每日图像引导。
  • 剂量限制性毒性定义为归因于pexidartinib的3级毒性,本研究中5起3级毒性符合该标准。

临床怎么用

  • 该联合方案因剂量限制性毒性导致研究关闭,不支持在中危和高危前列腺癌中临床推广应用。
  • 临床应关注pexidartinib联合放疗和ADT时可能出现的3级毒性,如肺栓塞、疲劳、关节痛、淀粉酶升高和瘙痒。

局限性

  • 研究样本量小,仅4例患者可评估。
  • 研究因毒性提前关闭,未能确定最大耐受剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to evaluate a combination of radiation therapy (RT), androgen deprivation therapy (ADT), and pexidartinib (colony-stimulating factor 1 receptor [CSF1R]) inhibitor in men with intermediate- and high-risk prostate cancer. CSF1R signaling promotes tumor infiltration and survival of tumor-associated macrophages, which in turn promote progression and resistance. Counteracting protumorigenic actions of tumor-associated macrophages via CSF1R inhibition may enhance therapeutic efficacy of RT and ADT for prostate cancer. METHODS AND MATERIALS: In this phase 1 study, the treatment regimen consisted of pexidartinib (800 mg, administered as a split-dose twice daily) and ADT (both for a total of 6 months), and RT that was initiated at the start of month 3. RT volumes included the prostate and proximal seminal vesicles. The delivered dose was 7920 cGy (180 cGy per fraction) using intensity modulated RT with daily image guidance for prostate localization. The primary objective was to identify the maximum tolerated dose based on dose-limiting toxicities. RESULTS: All 4 enrolled patients who were eligible to receive RT had T1 stage prostate cancer, 2 were intermediate risk, and 2 were high risk. The median age was 62.5 years, and the prostate-specific antigen levels were in the range 6.4 to 10.7 ng/mL. The patients' individual Gleason scores were 3 + 3, 4 + 3, 4 + 4, and 4 + 5. All 4 patients reported ≥1 adverse events before RT. Grade 1 hypopigmentation was observed in 1 patient, and grade 3 pulmonary embolus in another. One patient experienced fatigue and joint pain, and another elevated amylase and pruritus (all grade 3 toxicities). Five of the 6 adverse events noted in 3 patients were all grade 3 toxicities attributable to pexidartinib, qualifying as dose-limiting toxicities and ultimately resulting in the study closure. CONCLUSIONS: The combination was not well tolerated and does not warrant further investigation in men with intermediate- and high-risk prostate cancer.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Hamid M, Heilbrun LK, Maier J, et al. A Phase 1 study Combining Pexidartinib, Radiation Therapy, and Androgen Deprivation Therapy in Men With Intermediate- and High-Risk Prostate Cancer. Adv Radiat Oncol. 2021. PMID: 34286163. doi:10.1016/j.adro.2021.100679

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。